OCF Yield % is calculated as Cash Flow from Operations divided by Market Capitalization. It is a financial solvency ratio that compares the operating cash flow a company is expected to earn against its market value.
Similar to Earnings Yield %, OCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high operating cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
BioStem Technologies OCF Yield % Related Terms
BioStem Technologies OCF Yield % Historical Data
* Premium members only.
The historical data trend for BioStem Technologies's OCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, BioStem Technologies's OCF Yield %, along with its competitors' market caps and OCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioStem Technologies OCF Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BioStem Technologies's OCF Yield % distribution charts can be found below:
* The bar in red indicates where BioStem Technologies's OCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioStem Technologies (BSEM) has a OCF Yield % of 40.20 as of Jun. 27, 2026. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on BioStem Technologies and its competitors. According to the industry distribution chart, BioStem Technologies ranks #7 out of 1419 companies in the Biotechnology industry, placing it in the top 0.5%.
Is BioStem Technologies' OCF Yield % too high?
BioStem Technologies' current OCF Yield % is 40.20. Based on the distribution chart, BioStem Technologies ranks #7 out of 1419 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, BioStem Technologies has a GF Score™ of 49/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does BioStem Technologies' OCF Yield % compare to TCRX and BYSI?
According to the Biotechnology industry distribution chart, BioStem Technologies ranks #7 out of 1419 companies for OCF Yield %. This places BioStem Technologies in the top 1% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Yield % for a Biotechnology company?
A good OCF Yield % depends on the Biotechnology industry context. However, OCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Yield % mean?
A high OCF Yield % can signal that a stock is expensive relative to its fundamentals. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on BioStem Technologies and its competitors. BioStem Technologies's current OCF Yield % is 40.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioStem Technologies stock overvalued right now?
Based on GuruFocus' analysis, BioStem Technologies (BSEM) is currently considered Possible Value Trap. The stock's GF Value™ is $139.96, compared to a current price of $3.59 — trading 97.4% below its estimated fair value. The current OCF Yield % is 40.20. BioStem Technologies' overall GF Score™ is 49/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Yield % calculated?
OCF Yield % is calculated from a company's financial statements. For BioStem Technologies (BSEM), the current OCF Yield % is 40.20 as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BioStem Technologies (BSEM) Overvalued in 2026?
Based on GuruFocus' analysis, BioStem Technologies stock appears to be undervalued.
The current stock price of $3.59 is trading 97.4% below its estimated GF Value™ of $139.96.
GuruFocus considers BioStem Technologies to be Possible Value Trap.
Key valuation signals for BSEM:
OCF Yield %: 40.20
GF Value™: $139.96 vs. price of $3.59 (97.4% below fair value)
No single metric tells the full story. See the BSEM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BioStem Technologies Inc is a regenerative biotechnology company focused on harnessing elements of perinatal tissue and the body's innate biology to repair or reverse damage caused by a broad range of degenerative diseases. The company develops, manufactures, and sells tissue allografts for the wound care market with a focus on the treatment of diabetic, pressure, and venous ulcers. Utilizing its proprietary BioRetain processing method, it manufactures perinatal tissue allografts. The company offers a comprehensive portfolio of high-quality brands that are trademarked and include VENDAJE AC, AmnioWrap2, and Others. The company generates key revenue from VENDAJE AC.
49GF Score
Get the complete analysis for BSEM
OCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BSEM has been successfully added to your 
